I thought about your comments and I couldn't find one good reason for holding the trials in indonesia. It's difficult to understand why trials can't be done in Australia or the USA unless the company doesn't actually believe the product would succeed and is not prepared to take the chance of public failure. I find it hard to believe that infomally they do not already have a very good idea if the trials would work or not, so I reduced my holding in RCE by 2/3rds and will just wait and see what happens
Ann: R327 Efficacy against WHO Priority Pathogen Acinetobacter B, page-21
Add RCE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
54.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $125.2M | |||
| Open | High | Low | Value | Volume |
| 54.0¢ | 54.0¢ | 54.0¢ | $980 | 1.814K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 11280 | 52.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 53.5¢ | 15244 | 2 |
View Market Depth
| Last trade - 10.06am 14/10/2024 (20 minute delay) ? |
| RCE (ASX) Chart |